Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | TPMT | P51580 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.44 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2439167 | 0.87 | CYP19A1 (0.45) | CYP3A4CYP1A2CYP2C9CYP2C19TSHR | |
| SCHEMBL10246834 | 0.87 | L3MBTL1 (0.42) | CYP3A4CYP1A2CYP2C9CYP2C19TSHR | |
| SCHEMBL5697959 | 0.85 | MAPT (0.50) | CYP3A4CYP1A2CYP2C9CYP2C19TSHR | |
| SCHEMBL602723 | 0.85 | CA12 (0.52) | CYP3A4CYP1A2CYP2C9CYP2C19TSHR | |
| SCHEMBL10227971 | 0.84 | KMO (0.43) | CYP3A4CYP1A2CYP2C9CYP2C19KMT2A | |
| SCHEMBL601612 | 0.84 | AKR1C3 (0.43) | — | |
| SCHEMBL19286758 | 0.84 | CYP1A2 (0.47) | CYP3A4CYP1A2CYP2C9CYP2C19TSHR | |
| SCHEMBL5493759 | 0.84 | CNR1 (0.51) | CYP3A4CYP1A2CYP2C9CYP2C19TSHR | |
| SCHEMBL7583554 | 0.82 | ALDH1A1 (0.44) | TSHRTDP1ALDH1A1 | |
| SCHEMBL14862610 | 0.80 | L3MBTL1 (0.47) | CYP3A4CYP1A2CYP2C9CYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2871187-B1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2017-09-20 | — | — | EP | disclosed |
| US-9745280-B2 | Compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient | SNU R&DB FOUNDATION (KR) | 2017-08-29 | — | — | US | disclosed |
| US-20160340331-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2016-11-24 | — | — | US | disclosed |
| US-20150183797-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2015-07-02 | — | — | US | disclosed |
| WO-2013054338-A1 | 2-THIO-IMIDAZOLE DERIVATIVES AS TGR5 MODULATORS | CADILA HEALTHCARE LIMITED (IN) | 2013-04-18 | — | — | WO | disclosed |
| WO-2013054338-A1 | 2-THIO-IMIDAZOLE DERIVATIVES AS TGR5 MODULATORS | CADILA HEALTHCARE LIMITED (IN) | 2013-04-18 | — | — | WO | disclosed |
| EP-0407588-B1 | PROCESS FOR PRODUCING 2-OXO-3-AROMATIC CARBOXYLIC ACID DERIVATIVES | SAGAMI CHEM RES (JP) | 1993-12-08 | — | — | EP | disclosed |
| US-5028738-A | Process for producing 2-oxo-3-aromatic carboxylic acid derivatives | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1991-07-02 | — | — | US | disclosed |
| EP-0407588-A1 | PROCESS FOR PRODUCING 2-OXO-3-AROMATIC CARBOXYLIC ACID DERIVATIVES | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1991-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183797-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | HSP90AB1, HSP90AA1, HIF1AN | CYP3A4 4301/4885CYP1A2 3529/4885CYP2C9 3186/4885 |
| US-20160340331-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | HSP90AB1, HSP90AA1, HSP90AB2P | CYP3A4 4358/4885CYP1A2 3462/4885CYP2C9 3281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.